Share on StockTwits

DaVita HealthCare Partners (NYSE:DVA) was upgraded by analysts at Ned Davis Research from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Monday, American Banking News.com reports.

Several other analysts have also recently commented on the stock. Analysts at Citigroup Inc. reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note on Thursday. They now have a $71.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note on Thursday, April 10th. They now have a $73.00 price target on the stock. Finally, analysts at Deutsche Bank raised their price target on shares of DaVita HealthCare Partners from $72.00 to $74.00 in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. DaVita HealthCare Partners has an average rating of “Hold” and a consensus price target of $87.89.

DaVita HealthCare Partners (NYSE:DVA) traded down 0.36% on Monday, hitting $69.26. 494,651 shares of the company’s stock traded hands. DaVita HealthCare Partners has a 1-year low of $52.75 and a 1-year high of $70.68. The stock has a 50-day moving average of $68.67 and a 200-day moving average of $63.11. The company has a market cap of $14.766 billion and a P/E ratio of 23.55.

DaVita HealthCare Partners (NYSE:DVA) last announced its earnings results on Tuesday, February 11th. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.91 by $0.92. The company had revenue of $3.06 billion for the quarter, compared to the consensus estimate of $2.92 billion. During the same quarter in the previous year, the company posted $1.68 earnings per share. The company’s revenue for the quarter was up 23.6% on a year-over-year basis. On average, analysts predict that DaVita HealthCare Partners will post $3.67 earnings per share for the current fiscal year.

DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.